Clinical Trial Update: CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of CD123-directed T-cell therapy for acute myeloid leukemia and related hematologic diseases is currently recruiting (CATCHAML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Myelodysplastic Syndromes
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD123-directed T-cell therapy (CD123-directed T-cell therapy)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: AML/MDS, B-ALL | Phase 1 | Status: RECRUITING